Hangzhou Dingle New Biotechnology

Hangzhou Dingle New Biotechnology is a Chinese biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases. The company specializes in metabolic regulation, particularly targeting the incretin system with multi-agonist peptides and small molecules. Their research efforts are primarily directed toward addressing high-prevalence conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging advanced peptide engineering and medicinal chemistry, the firm aims to develop next-generation treatments with improved efficacy and safety profiles compared to existing standards of care.